# Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

Study · id `cardio:ct-nct01336140` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01336140](<https://clinicaltrials.gov/study/NCT01336140>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01336140

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT01336140. Randomized; quadruple masking; primary purpose prevention. Start 2011-06 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2013-02-13.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT01336140, source copy `cardio:ctgov-nct01336140-2023-01-26`, retrieved 2026-10-26)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01336140, source copy `cardio:ctgov-nct01336140-2023-01-26`, retrieved 2026-10-26)
- Primary completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01336140, source copy `cardio:ctgov-nct01336140-2023-01-26`, retrieved 2026-10-26)
- Completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01336140, source copy `cardio:ctgov-nct01336140-2023-01-26`, retrieved 2026-10-26)
- Results first posted: 2013-02-13 (ClinicalTrials.gov record NCT01336140, source copy `cardio:ctgov-nct01336140-2023-01-26`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01336140, source copy `cardio:ctgov-nct01336140-2023-01-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01336140-2023-01-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging
- Acronym: ASSUAGE-CKD
- Condition: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
- Intervention (Drug): Aminophylline
- Intervention (Drug): Placebo
- Lead sponsor: Rush University Medical Center
- Lead sponsor class: OTHER
- Collaborator: Cook County Health
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Rush University Medical Center (`cardio:org-rush-university-medical-center`)
- Registry lists this organization as a collaborator: Cook County Health (`cardio:org-cook-county-health`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial (`cardio:pubmed-23224354`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cdb2f72ff663eada39c1188a715a5309d8400a21b04b089daa7b3b26d9720fee
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
